Modality
Bispecific Ab
MOA
PARPi
Target
MALT1
Pathway
mTOR
PNH
Development Pipeline
Preclinical
~Sep 2020
→ ~Dec 2021
Phase 1
~Mar 2022
→ ~Jun 2023
Phase 2
Sep 2023
→ Sep 2030
Phase 2Current
NCT07857720
1,046 pts·PNH
2023-09→2030-09·Not yet recruiting
1,046 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-274.5y awayPh2 Data· PNH
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Not yet…
Catalysts
Ph2 Data
2030-09-27 · 4.5y away
PNH
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07857720 | Phase 2 | PNH | Not yet recr... | 1046 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF |